BP brings in reverse auction as it pushes ahead with panel review

BP has introduced a reverse auction into its latest panel tender process, an announcement which comes in the same week as the energy giant lost an appeal to restrict access to its $20bn compensation fund for the Deepwater Horizon disaster. The FTSE 100 company confirmed this morning (22 May) that it has issued invites to existing and potential panel member firms, and revamped the process with the introduction of an online reverse auction element to make the bidding process more transparent, quicker and efficient.  Continue reading “BP brings in reverse auction as it pushes ahead with panel review”

Breathing space for MOJ as Court of Appeal orders OpCotton trial to resume

In a verdict that gives the Ministry of Justice at least a temporary reprieve in its legal aid battle with the Bar, the Court of Appeal today (21 May) reversed the Crown Court’s ruling that the ‘OpCotton’ serious fraud trial should be stayed after the defendants failed to find any barrister prepared to represent them on reduced legal aid rates.

Continue reading “Breathing space for MOJ as Court of Appeal orders OpCotton trial to resume”

Deal Watch: Freshfields advises Blackstone on €1.8bn NAMA loan; CC and A&O close €2.8bn offshore wind financing

Freshfields Bruckhaus Deringer has led on the latest major European mandate for Blackstone, advising the New York Stock Exchange-listed private equity group on its acquisition of a €1.8bn portfolio of cross-border loans and swaps from the National Asset Management Agency (NAMA) in Ireland. Continue reading “Deal Watch: Freshfields advises Blackstone on €1.8bn NAMA loan; CC and A&O close €2.8bn offshore wind financing”

Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)

In front of the Commons Business committee last week, Ian Read, chairman and chief executive of Pfizer, made two points in relation to Pfizer’s commitments, assuming it were to succeed in acquiring the Anglo-Swedish drug manufacturer AstraZeneca. Continue reading “Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)”

ITV pulls in panel firms in new development programme as it launches ‘gold plated’ CSR scheme

ITV is taking steps to embed its law firms in the fabric of the organisation by involving them in a new programme of training and development with its lawyers, as it also launches a new, extensive social mobility iniative involving private practice pairings with Microsoft, Yahoo and MTV. Continue reading “ITV pulls in panel firms in new development programme as it launches ‘gold plated’ CSR scheme”